Most Recent
Philips Electronics has hit back at a class action over recalled sleep apnea machines that contained a foam component that could allegedly degrade and cause consumers to inhale dangerous chemicals, saying the devices were not defective when they were sold.
Two psychiatrists who administered the controversial deep sleep therapy at the Chelmsford Private Hospital in the 1970s have won a Full Federal Court appeal in their defamation cases against publisher HarperCollins, with one of the cases being sent back for a re-trial.
Settlement talks in three class actions on behalf of women injured by allegedly defective pelvic mesh products have progressed “substantially”, a court has heard.
A Gold Coast cosmetic surgeon has won his defamation case against a competitor who posted a phony online review, with a judge ordering damages of more than $450,000.
The maker of the popular Invisalign dental aligners may soon face a cross-claim from competitor SmileDirectClub, which it sued for allegedly misleading consumers about the cost and efficacy of its direct-to-consumer teeth alignment kits.
The Full Federal Court won't give Swiss pharmaceuticals giant Novartis the chance to appeal a ruling that threw out three of its four experts in a patent case against generic drug maker Pharmacor.
An additional 1,200 women who were implanted with defective pelvic mesh devices will be eligible for compensation after Johnson & Johnson unit Ethicon agreed that findings in an earlier class action which it unsuccessfully fought all the way to the High Court should apply to a follow-on class action.
A judge has declined to award costs against a group of nurses who recently dropped their Fair Work lawsuit against Monash Health, saying the case was not "doomed to fail" and noting the “extremity” of the Victorian government’s vaccine mandate for workers.
The competition regulator has proposed to deny authorisation for a patent settlement that sought to permit early entry of generic drugs. Whether the companies involved will be able to quell the ACCC's concerns remains to be seen, but what is clear is that future authorisation applications will contend with significant forensic challenges, writes Corrs Chambers Westgarth's Odette Gourley, Richard Flitcroft, David Fixler and Ian Reynolds.
The Federal Court has signed off on a settlement between two US biotech companies that ends a dispute over the companies' 'Access' trade marks in Australia.